Literature DB >> 18641313

TCR antagonism by peptide requires high TCR expression.

Daniel S Jones1, Peter Reichardt, Mandy L Ford, Lindsay J Edwards, Brian D Evavold.   

Abstract

Current models of T cell activation focus on the kinetics of TCR-ligand interactions as the central parameter governing T cell responsiveness. However, these kinetic parameters do not adequately predict all T cell behavior, particularly the response to antagonist ligands. Recent studies have demonstrated that TCR number is a critical parameter influencing the responses of CD4(+) T cells to weak agonist ligands, and receptor density represents an important means of regulating tissue responsiveness in other receptor ligand systems. To systematically address the impact of TCR expression on CD8(+) T cell responses, mAbs to the TCR alpha-chain and T cells expressing two TCR species were used as two different methods to manipulate the number of available TCRs on P14 and OT-I transgenic T cells. Both methods of TCR reduction demonstrated that the efficacy of antagonist peptides was significantly reduced on T cells bearing low numbers of available receptors. In addition, the ability of weak agonists to induce proliferation was critically dependent on the availability of high numbers of TCRs. Therefore, in this report we show that TCR density is a major determinant of CD8(+) T cell reactivity to weak agonist and antagonist ligands but not agonist ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641313     DOI: 10.4049/jimmunol.181.3.1760

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

Review 2.  T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.

Authors:  Lindsay J Edwards; Brian D Evavold
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

3.  Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE.

Authors:  Maria Bettini; Kristen Rosenthal; Brian D Evavold
Journal:  J Neuroimmunol       Date:  2009-06-21       Impact factor: 3.478

4.  A unique unresponsive CD4+ T cell phenotype post TCR antagonism.

Authors:  Lindsay J Edwards; Brian D Evavold
Journal:  Cell Immunol       Date:  2009-12-23       Impact factor: 4.868

5.  Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.

Authors:  Sharyn Thomas; Fiyaz Mohammed; Rogier M Reijmers; Annemarie Woolston; Theresa Stauss; Alan Kennedy; David Stirling; Angelika Holler; Louisa Green; David Jones; Katherine K Matthews; David A Price; Benjamin M Chain; Mirjam H M Heemskerk; Emma C Morris; Benjamin E Willcox; Hans J Stauss
Journal:  Nat Commun       Date:  2019-10-01       Impact factor: 14.919

Review 6.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Authors:  Martín Candia; Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-09-20       Impact factor: 2.749

7.  Cross-TCR Antagonism Revealed by Optogenetically Tuning the Half-Life of the TCR Ligand Binding.

Authors:  Omid Sascha Yousefi; Matias Ruggieri; Vincent Idstein; Kai Uwe von Prillwitz; Laurenz A Herr; Julia Chalupsky; Maja Köhn; Wilfried Weber; Jens Timmer; Wolfgang W A Schamel
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

8.  Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.

Authors:  Ruey-Shyang Soong; Liwen Song; Janson Trieu; Sung Yong Lee; Liangmei He; Ya-Chea Tsai; T-C Wu; Chien-Fu Hung
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.